A New Model for Bone Health Management in Postmenopausal Early Breast Cancer Patients Undergoing Adjuvant Endocrine Therapy—The Predict & Prevent Project
Stefania Gori(Ospedale Sacro Cuore Don Calabria), Fabrizio Nicolis(Ospedale Sacro Cuore Don Calabria), Matteo Verzè(Ospedale Sacro Cuore Don Calabria), Armando Orlandi(Agostino Gemelli University Polyclinic), Ferdinando Riccardi(Ospedale Antonio Cardarelli), Saverio Cinieri(Ospedale A. Perrino), Fabio Puglisi(University of Udine), Tiziana Prochilo(Fondazione Poliambulanza Istituto Ospedaliero), Rossana Berardi(Marche Polytechnic University), Claudia Bighin(Azienda Ospedaliera S.Maria), Alberto Zaniboni(Fondazione Poliambulanza Istituto Ospedaliero), Roberto Tessari(Ospedale Sacro Cuore Don Calabria), Mario Airoldi, Carlotta Mantoan, Alessandro Del Conte(University of Catania), Paola Villa(Agostino Gemelli University Polyclinic), Alessandra Chirco(Ospedale Papa Giovanni XXIII), Martina Assanti, Matteo Valerio(Ospedale Sacro Cuore Don Calabria)
Cited by 0
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k